@article {138, editor = {,}, title = {â–¼Naloxegol for opioid-induced constipation}, volume = {53}, number = {12}, pages = {138--140}, year = {2015}, doi = {10.1136/dtb.2015.12.0369}, publisher = {British Medical Journal Publishing Group}, abstract = {â–¼Naloxegol (Moventig{\textemdash}AstraZeneca) is a peripherally acting mu-opioid receptor antagonist licensed for the treatment of opioid-induced constipation in adults who have had an inadequate response to laxative treatment.1 It was launched in the United Kingdom in October 2015. Here, we review the evidence for naloxegol and consider its place in the management of opioid-induced constipation.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/53/12/138}, eprint = {https://dtb.bmj.com/content/53/12/138.full.pdf}, journal = {Drug and Therapeutics Bulletin} }